摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-(β-D-arabinofuranosyl)adenine | 38948-23-1

中文名称
——
中文别名
——
英文名称
9-(β-D-arabinofuranosyl)adenine
英文别名
adenine-9-beta-arabinofuranoside;adenine-9-β-D-arabinofuranoside;6-Amino-9H-purin-9-yl beta-D-arabinofuranoside;(2S,3S,4S,5R)-2-(6-aminopurin-9-yl)oxy-5-(hydroxymethyl)oxolane-3,4-diol
9-(β-D-arabinofuranosyl)adenine化学式
CAS
38948-23-1
化学式
C10H13N5O5
mdl
——
分子量
283.244
InChiKey
QWCJDHIDJGFBKT-KMPDEGCQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.4
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    149
  • 氢给体数:
    4
  • 氢受体数:
    9

文献信息

  • Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside
    申请人:——
    公开号:US20020193314A1
    公开(公告)日:2002-12-19
    A desired isomer is selectively prepared by phosphorolyzing and isomerizing an anomer mixture of a 1-phosphorylated saccharide derivative while crystallizing one of the isomers to displace the equilibrium. Furthermore, using the action of a nucleoside phosphorylase, a nucleoside is prepared from the 1-phosphorylated saccharide derivative obtained and a base with improved stereoselectivity and a higher yield. This process is an anomer-selective process for preparing a 1-phosphorylated saccharide derivative and a nucleoside.
    通过磷酸解和异构化1-磷酸化糖衍生物的环式异构体混合物,有选择性地制备所需的异构体,同时通过结晶其中一种异构体以移动平衡。此外,利用核苷酸磷酸化酶的作用,从获得的1-磷酸化糖衍生物和一种改善立体选择性和更高产率的碱基中制备核苷酸。该过程是用于制备1-磷酸化糖衍生物和核苷酸的环式选择性过程。
  • Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside
    申请人:Komatsu Hironori
    公开号:US20060094869A1
    公开(公告)日:2006-05-04
    A desired isomer is selectively prepared by phosphorolyzing and isomerizing an anomer mixture of a 1-phosphorylated saccharide derivative while crystallizing one of the isomers to displace the equilibrium. Furthermore, using the action of a nucleoside phosphorylase, a nucleoside is prepared from the 1-phosphorylated saccharide derivative obtained and a base with improved stereoselectivity and a higher yield. This process is an anomer-selective process for preparing a 1-phosphorylated saccharide derivative and a nucleoside.
    通过磷酸解和异构化1-磷酸化糖衍生物的异构体混合物,有选择性地制备所需的异构体,并结晶其中一种异构体以移动平衡。此外,利用核苷酸磷酸化酶的作用,从所得的1-磷酸化糖衍生物和碱基中制备核苷,具有改善的立体选择性和更高的产量。该过程是一种选择性异构过程,用于制备1-磷酸化糖衍生物和核苷。
  • TOPICAL FORMULATIONS
    申请人:BECK Petra Helga
    公开号:US20100093691A1
    公开(公告)日:2010-04-15
    There is provided topical pharmaceutical compositions comprising compounds of formula I wherein R 1 , R 2 , R 3 and X have meanings given in the description. These compositions can be used to treat microbial infections and to kill clinically latent microorganisms.
    提供了一种含有I式化合物的局部制药组合物,其中R1、R2、R3和X的含义在说明中给出。这些组合物可用于治疗微生物感染并杀死临床潜伏微生物
  • INHIBITORS OF E1 ACTIVATING ENZYMES
    申请人:Critchley Stephen
    公开号:US20110136834A1
    公开(公告)日:2011-06-09
    This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    本发明涉及抑制E1激活酶的化合物、包含该化合物的药物组合物以及使用该化合物的方法。该化合物可用于治疗疾病,特别是细胞增殖障碍,包括癌症、炎症和神经退行性疾病;以及与感染和消瘦相关的炎症。
  • USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS
    申请人:Beck Petra Helga
    公开号:US20120231995A1
    公开(公告)日:2012-09-13
    There is provided the use of compounds of formula I wherein R 1 , R 2 , R 3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.
    提供了使用式子I中的化合物,其中R1、R2、R3和X的含义在说明中给出,用于制备杀死临床潜伏微生物的药物。还提供了使用式子I中的化合物治疗微生物感染的方法,以及某些式子I中的化合物本身。
查看更多